Subject(s)
Antibodies, Monoclonal, Humanized/therapeutic use , Immunoglobulin G/therapeutic use , Psoriasis/drug therapy , Receptors, Tumor Necrosis Factor/therapeutic use , Seasons , Tumor Necrosis Factor-alpha/antagonists & inhibitors , Adalimumab , Adolescent , Adult , Etanercept , Humans , Middle Aged , Psoriasis/physiopathology , Young AdultABSTRACT
No disponible
Subject(s)
Humans , Male , Child , Hypertrichosis/chemically induced , Diazoxide/adverse effects , Hypoglycemia/drug therapySubject(s)
Diazoxide/adverse effects , Hypertrichosis/chemically induced , Child , Humans , Hypertrichosis/pathology , MaleABSTRACT
BACKGROUND: Tuberous sclerosis complex (TSC) is an autosomal dominant neurocutaneous disorder characterized by the development of multisystem hamartomatous tumours. Facial angiofibroma appears in up to 80% of patients and has a considerable psychological impact. Various invasive procedures have been used, although they show limited effectiveness and potential adverse effects. OBJECTIVES: To evaluate the sustained clinical benefits and safety profile of topical sirolimus applied to treat facial angiofibromas. METHODS: This study was a non-blinded, uncontrolled case-series comprising 10 patients with TSC-associated facial angiofibroma that was treated with 0.4% sirolimus ointment 3 times a week for 9 months. Patients were clinically evaluated at baseline and at 6, 12, 24 and 36 weeks. Plasma levels of sirolimus were determined. RESULTS: A sustained improvement was observed in erythema and in the size and extension of the lesions as early as the first weeks of treatment. Sirolimus plasma levels remained below detection limits (0.3 ng/mL) in all cases. The formula was well-tolerated with no local or systemic adverse effects. CONCLUSIONS: Topical sirolimus seems to be an effective and safe medical alternative to surgery or laser-based treatments in patients with TSC-associated facial angiofibromas.
Subject(s)
Angiofibroma/etiology , Immunosuppressive Agents/therapeutic use , Sirolimus/therapeutic use , Tuberous Sclerosis/drug therapy , Administration, Topical , Adolescent , Adult , Child , Face , Female , Humans , Immunosuppressive Agents/adverse effects , Male , Middle Aged , Sirolimus/adverse effects , Tuberous Sclerosis/complications , Young AdultABSTRACT
La enfermedad de Darier segmentaria es una variante rara de esta patológica. Se caracteriza por una (..) (AU)
Segmental Darier disease is an unusual form of this condition. It is characterized by the localized (..) (AU)
Subject(s)
Humans , Male , Adult , Darier Disease/diagnosis , Warts/diagnosis , Lactic Acid/therapeutic use , Genetic Predisposition to DiseaseABSTRACT
No disponible
No disponible
Subject(s)
Humans , Male , Adult , Alopecia/etiology , Aneurysm/surgery , Middle Cerebral Artery , Headache/etiology , Aneurysm/complications , Angiography/methods , Fluoroscopy/adverse effects , Photosensitivity DisordersSubject(s)
Hyperpigmentation/genetics , Hypopigmentation/genetics , Child , Child, Preschool , Growth Disorders/genetics , Humans , Male , Pedigree , SyndromeABSTRACT
This paper presents a minimally invasive needle-shaped probe capable of monitoring the electrical impedance of living tissues. This microprobe consists of a 160 microm thick SU-8 substrate containing four planar platinum (Pt) microelectrodes. We design the probe to minimize damage to the surrounding tissue and to be stiff enough to be inserted in living tissues. The proposed batch fabrication process is low cost and low time consuming. The microelectrodes obtained with this process are strongly adhered to the SU-8 substrate and their impedance does not depend on frequency variation. In vitro experiments are compared with previously developed Si and SiC based microprobes and results suggest that it is preferable to use the SU-8 based microprobes due to their flexibility and low cost. The microprobe is assembled on a flexible printed circuit FPC with a conductive glue, packaged with epoxy and wired to the external instrumentation. This flexible probe is inserted into a rat kidney without fracturing and succeeds in demonstrating the ischemia monitoring.
